Cargando…

Are you treating ypN0 patient with adjuvant abemaciclib?

Detalles Bibliográficos
Autores principales:	Toss, A., Moscetti, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147964/ https://www.ncbi.nlm.nih.gov/pubmed/37079950 http://dx.doi.org/10.1016/j.esmoop.2023.101217

Ejemplares similares

Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0
por: You, Kai-yun, et al.
Publicado: (2014)

Impact of adjuvant chemotherapy on patients with ypT0–2 ypN0 rectal cancer after neoadjuvant chemoradiation: a cohort study from a tertiary referral hospital
por: Galata, Christian, et al.
Publicado: (2018)

Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy
por: Trotsyuk, Iryna, et al.
Publicado: (2019)

The Benefit of Post-Mastectomy Radiotherapy in ypN0 Patients after Neoadjuvant Chemotherapy According to Molecular Subtypes
por: Cho, Won Kyung, et al.
Publicado: (2019)

The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy: a meta-analysis
por: Wang, Ke, et al.
Publicado: (2021)

Nomogram to predict ypN status after chemoradiation in patients with locally advanced rectal cancer
por: Jwa, E, et al.
Publicado: (2014)

Risk factors for long-term survival in patients with ypN+ M0 rectal cancer after radical anterior resection
por: Zeman, Marcin, et al.
Publicado: (2022)

Duration of Perioperative Chemotherapy in Locally Advanced Gastric Cancer: A “Less Is More” Question When ypN0 Is Achieved
por: Liu, Zining, et al.
Publicado: (2021)

Adjuvant chemotherapy may be unnecessary for ypT0-2N0 gastric cancer patients after neoadjuvant chemotherapy and curative gastrectomy
por: Shao, Xinxin, et al.
Publicado: (2023)

Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer
por: Fukada, Ippei, et al.
Publicado: (2016)

The assessment of risk factors for long-term survival outcome in ypN0 patients with rectal cancer after neoadjuvant therapy and radical anterior resection
por: Zeman, Marcin, et al.
Publicado: (2021)

Axillary response and outcome in breast cancer patients after neoadjuvant treatment: The role of radiotherapy in reducing recurrence in ypN0 patients with initially cN+ stage
por: Ren, Xiaoqiu, et al.
Publicado: (2023)

The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer
por: Yang, Tian, et al.
Publicado: (2023)

Fat clearance and conventional fixation identified ypN0 rectal cancers following intermediate neoadjuvant radiotherapy have similar long-term outcomes
por: Chen, Nan, et al.
Publicado: (2019)

The impact of postmastectomy radiotherapy on cT1-2N1 breast cancer patients with ypN0 after neoadjuvant chemotherapy: a retrospective study based on real-world data
por: Dai, Yuran, et al.
Publicado: (2023)

Is adjuvant chemotherapy necessary for patients with ypT0–2N0 rectal cancer treated with neoadjuvant chemoradiotherapy and curative surgery?
por: Lu, Zhao, et al.
Publicado: (2018)

Reply to Hsueh YP et al.
por: Nambot, Sophie, et al.
Publicado: (2020)

Evaluating the benefit of adjuvant chemotherapy in patients with ypT0–1 rectal cancer treated with preoperative chemoradiotherapy
por: Jeon, Ye Won, et al.
Publicado: (2021)

Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients
por: Kim, Won Hwa, et al.
Publicado: (2018)

Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery
por: Kim, Chang Gon, et al.
Publicado: (2017)

Multiple brain metastases in a patient with ypT0N0 micropapillary urothelial carcinoma of the bladder
por: Kuppa, Srikar, et al.
Publicado: (2021)

Oncologic effects of adjuvant chemotherapy in patients with ypT0–2N0 rectal cancer after neoadjuvant chemoradiotherapy and curative surgery: a meta-analysis
por: Ha, Gi Won, et al.
Publicado: (2020)

Postoperative radiotherapy improves survival of patients with ypN2 non‐small cell lung cancer after neoadjuvant chemotherapy followed by surgery – A propensity score matching study of the Surveillance, Epidemiology, and End Results database
por: Bao, Yongxing, et al.
Publicado: (2021)

Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis
por: Kuo, Yu-Hsuan, et al.
Publicado: (2022)

Does postoperative chemotherapy improve overall survival of patients with ypT1-2N0 cancer?
por: Su, Pengfei, et al.
Publicado: (2022)

Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer
por: Naiken, Surennaidoo P, et al.
Publicado: (2014)

Impact of Adjuvant Chemotherapy Completion on Oncologic Outcomes in ypTNMstage 2 Rectal Cancer Patients
por: Park, Youn Young, et al.
Publicado: (2019)

PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS
por: ANDREOLLO, Nelson Adami, et al.
Publicado: (2018)

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib
por: Modi, Natansh D., et al.
Publicado: (2021)

Abemaciclib for breast cancer
Publicado: (2020)

Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
por: Toi, Masakazu, et al.
Publicado: (2022)

YpT1-2N0 rectal cancer after neoadjuvant chemoradiation has lower survival compared with pT1-2N0 rectal cancer
por: Wan, Jue-feng, et al.
Publicado: (2015)

Can Elevated Pretreatment Serum Carcinoembryonic Antigen Levels Serve as a Potential Biomarker Guiding Adjuvant Chemotherapy in Rectal Cancer Patients With ypTis-3N0 After Neoadjuvant Radiotherapy and Surgery?
por: Huang, Chi, et al.
Publicado: (2021)

A Dilemma in Staging of Esophageal Cancer: How Should We Stage ypT0 N2 M0 Esophageal Cancer after Neoadjuvant Therapy?
por: Celik, Sebahattin, et al.
Publicado: (2015)

Response to: COVID-related upsurge in diagnoses of advanced breast cancer—is a disruption in mammography screening the one to be blamed?
por: Toss, A.
Publicado: (2021)

Predicting stage ypT0–1N0 for nonradical management in patients with middle or low rectal cancer who undergo neoadjuvant chemoradiotherapy: a retrospective cohort study
por: Lee, Jeehye, et al.
Publicado: (2022)

Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center
por: Dannehl, Dominik, et al.
Publicado: (2022)

Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy
por: Koo, Taeryool, et al.
Publicado: (2015)

Open and closed conformations of two SpoIIAA-like proteins (YP_749275.1 and YP_001095227.1) provide insights into membrane association and ligand binding
por: Kumar, Abhinav, et al.
Publicado: (2009)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vtul9ev5fejtarku0u176u6oj5